iProTide

Enhancing Proteins to Create New Treatments for Diabetes

Health Tech & Life Sciences
Non Active, Dec 2016
Pre-Funding Modi'in-Maccabim-Re'ut, Israel Founded 2010
Last updated 2026-06-18
Total raised
Stage
Pre-Funding
Founded
2010
Headcount
6
HQ
Modi'in-Maccabim-Re'ut, Israel
Sector
Health Tech & Life Sciences

About

iProTide seeks to enhance protein-based drug discovery through innovations related to the physical, chemical, and biological properties of amino acids. Initially, the company plans to focus on peptides and proteins associated with obesity and diabetes. There is an unmet need for proteins/peptides that are efficacious in very small doses (high bio-availability), stable, and specific. iProTides technology is based on chemical modifications made within the backbone of proteins and amino acids without altering the side chain. These chemical modifications will potentially give rise to enhanced proteins with better stability and with distinct folding properties. They could also enhance the activity and specificity of these proteins/peptides. The changes will be tested for their potential in enhancing the efficiency of known peptide-based therapeutics, and mayenable the re-use of peptides/proteins that failed clinical trials due to PK/PD, toxicity, and efficiency issues.

Q&A

What is iProTide's primary focus in drug discovery?
iProTide focuses on enhancing protein-based drug discovery through innovations in the physical, chemical, and biological properties of amino acids, initially targeting peptides and proteins related to obesity and diabetes.
What is the core technology behind iProTide's approach?
iProTide's technology involves chemical modifications within the backbone of proteins and amino acids, without altering the side chain, to potentially improve stability, folding properties, activity, and specificity of these proteins/peptides.
When was iProTide founded?
iProTide was founded in January 2010.
What is the current status of iProTide?
iProTide is currently inactive, as of December 2016.
Where is iProTide headquartered?
iProTide is headquartered in Modi'in-Maccabim-Re'ut, Center District, Israel.
Who is the founder of iProTide?
The founder of iProTide is Ronen Shemesh, PhD.
What is iProTide's current funding stage?
iProTide is in the Pre-Funding stage.

Team · 1

Founder · Founder
LinkedIn ↗

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B

Highlights

Verified

Tags

obesitypharmaceuticalsdiabetesdrug-discovery
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

Identifiers & details

Founded2010-1
Employees (exact)6
Status reasonNon Active, Dec 2016